Contact this trialFirst, we need to learn more about you.
Cyclin-Dependent Kinase (CDK) Inhibitor
Abemaciclib + Darolutamide for Advanced Prostate Cancer
Recruiting1 awardPhase 1
Springdale, Arkansas
This trial is testing the safety of two drugs, abemaciclib and darolutamide, in men whose prostate cancer has spread after initial treatment. The study aims to see if these drugs can be safely used together. Darolutamide is a new drug approved for treating a specific type of prostate cancer and has shown effectiveness in delaying the spread of the disease.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service